• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

    11/6/23 8:08:25 AM ET
    $ACXP
    $ADCT
    $AFMD
    $ASTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACXP alert in real time by email

    Gainers

    • Carbon Revolution Public Limited (NASDAQ:CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge Capital Acquisition Corp.
    • Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) shares rose 25.8% to $0.8686 in pre-market trading. Sensei Biotherapeutics reported clinical data for SNS-101 at 2023 SITC Annual Meeting.
    • Digital Brands Group, Inc. (NASDAQ:DBGI) shares gained 21.7% to $5.28 in pre-market trading after falling around 4% on Friday.
    • Warrantee Inc. (NASDAQ:WRNT) rose 21.4% to $0.45 in pre-market trading after gaining 11% on Friday.
    • RiceBran Technologies (NASDAQ:RIBT) shares climbed 21% to $0.4744 in pre-market trading after gaining 7% on Friday.
    • POSCO Holdings Inc. (NYSE:PKX) shares jumped 18.1% to $98.51 in pre-market trading. Shares of South Korea ADRs and ETFs gained following government ban on short selling through first half of next year.
    • Near Intelligence, Inc. (NASDAQ:NIR) rose 16.7% to $0.1997 in pre-market trading after gaining over 10% on Friday.
    • SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares rose 16.7% to $1.12 in pre-market trading. SELLAS Life Sciences recently announced a $4 million registered direct offering.
    • Missfresh Limited (NASDAQ:MF) gained 14.1% to $0.89 in pre-market trading after falling around 6% on Friday.
    • BEST Inc. (NYSE:BEST) shares rose 12.1% to $2.68 in pre-market trading. BEST announced receipt of a preliminary non-binding proposal to acquire the company.

    Losers

    • RiskOn International, Inc. (NASDAQ:ROI) dipped 16.8% to $0.5737 in pre-market trading.
    • Benson Hill, Inc. (NYSE:BHIL) shares fell 16.5% to $0.3333 in pre-market trading after surging 58% on Friday.
    • ADC Therapeutics SA (NYSE:ADCT) shares fell 16% to $0.6720 in pre-market trading after jumping 14% on Friday.
    • Affimed N.V. (NASDAQ:AFMD) shares fell 13.2% to $0.3166 in pre-market trading after gaining 4% on Friday.
    • Collective Audience, Inc. (NASDAQ:CAUD) fell 13.2% to $5.46 in pre-market after falling around 77% on Friday.
    • Mangoceuticals, Inc. (NASDAQ:MGRX) shares fell 11.4% to $0.5228 in pre-market trading.
    • Monopar Therapeutics Inc. (NASDAQ:MNPR) shares fell 10.8% to $0.4550 in pre-market trading.
    • The OLB Group, Inc. (NASDAQ:OLB) fell 10.1% to $0.5486 in pre-market trading.
    • Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) fell 9.5% to $2.97 in pre-market trading after declining around 14% on Friday.
    • Astra Space, Inc. (NASDAQ:ASTR) shares fell 8.5% to $0.84 in pre-market trading. Astra Space is expected to report financial results for its third quarter after market close on Nov. 13, 2023.

    Now Read This: Teradata Likely To Report Higher Q3 Earnings; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

    Get the next $ACXP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACXP
    $ADCT
    $AFMD
    $ASTR

    CompanyDatePrice TargetRatingAnalyst
    Monopar Therapeutics Inc.
    $MNPR
    1/9/2026$115.00Overweight
    Morgan Stanley
    Monopar Therapeutics Inc.
    $MNPR
    11/14/2025Strong Buy → Outperform
    Raymond James
    Monopar Therapeutics Inc.
    $MNPR
    11/10/2025$115.00Outperform
    Leerink Partners
    Monopar Therapeutics Inc.
    $MNPR
    10/13/2025$125.00Overweight
    Barclays
    Monopar Therapeutics Inc.
    $MNPR
    9/9/2025$87.00Buy
    BTIG Research
    Monopar Therapeutics Inc.
    $MNPR
    9/3/2025$77.00Outperform
    Oppenheimer
    Monopar Therapeutics Inc.
    $MNPR
    9/3/2025$80.00Strong Buy
    Raymond James
    Monopar Therapeutics Inc.
    $MNPR
    8/26/2025$70.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACXP
    $ADCT
    $AFMD
    $ASTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)

    4 - Monopar Therapeutics (0001645469) (Issuer)

    12/29/25 12:15:31 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kalin Katherine Bach bought $100,806 worth of shares (63,400 units at $1.59), increasing direct ownership by 155% to 104,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    11/21/25 8:45:10 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Van Nostrand Robert L bought $14,800 worth of shares (10,000 units at $1.48), increasing direct ownership by 96% to 20,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    6/13/25 8:00:33 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADCT
    $AFMD
    $ASTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Monopar Therapeutics with a new price target

    Morgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00

    1/9/26 9:05:54 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Monopar Therapeutics downgraded by Raymond James

    Raymond James downgraded Monopar Therapeutics from Strong Buy to Outperform

    11/14/25 9:54:47 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Monopar Therapeutics with a new price target

    Leerink Partners initiated coverage of Monopar Therapeutics with a rating of Outperform and set a new price target of $115.00

    11/10/25 8:46:42 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADCT
    $AFMD
    $ASTR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-5) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:04:01 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (SUPPL-4) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 10/12/2022. Application Category: BLA, Application Number: 761196, Application Classification:

    10/13/22 1:03:14 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

    Submission status for ADC Therapeutics SA's drug ZYNLONTA (ORIG-1) with active ingredient LONCASTUXIMAB TESIRINE-LPYL has changed to 'Approval' on 04/23/2021. Application Category: BLA, Application Number: 761196, Application Classification:

    4/23/21 1:46:03 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADCT
    $AFMD
    $ASTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

    NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that preclinical data on SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, will be presented in a poster session at the American Association for Cancer Research (AACR) taking place April 17-22 at San Diego Convention Center in San Diego, CA. The abstracts will be published in the online Proceedings of the AACR. Exposure of acute myeloid leukemia (AML) cell lines to increasing concentrations of SLS009 for 6 hours r

    3/17/26 4:30:00 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

    Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals," the "Company," or "MangoRx"), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has filed a civil lawsuit against Clarity Ventures, Inc., its former technology consulting and software development firm ("Clarity"). The lawsuit, filed in Texas state court, seeks damages exceeding $73 million, exclusive of interest, costs, and attorneys' fees. The Company alleges that Clarity failed to deliver a fully functional, HIPAA-compliant enterprise resource plann

    3/17/26 4:00:00 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that, effective on March 11, 2026, Sensei's Board of Directors granted a new employee an option to purchase 166,435 shares of the Company's common stock in connection with their employment (collectively, the "Option Award"). The Option Award was granted as an inducement material to the individual entering employment with Sensei in accordance with Nasdaq Listing Rule 5635(c)(4). The Option Award has an exercise price of $29.37, which is equal to the closing price of Sensei's common stock on March 11, 2026, and will vest, with respect to 25% of the shares subject to each such award, on the first anniversary of the date of grant, wit

    3/17/26 6:00:00 AM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADCT
    $AFMD
    $ASTR
    SEC Filings

    View All

    Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

    3/17/26 4:00:33 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    SEC Form EFFECT filed by ADC Therapeutics SA

    EFFECT - ADC Therapeutics SA (0001771910) (Filer)

    3/17/26 12:15:17 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by ADC Therapeutics SA

    424B3 - ADC Therapeutics SA (0001771910) (Filer)

    3/16/26 5:02:29 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADCT
    $AFMD
    $ASTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CCSO Rodriguez Susan

    4 - Monopar Therapeutics (0001645469) (Issuer)

    3/4/26 5:25:43 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Rodriguez Susan

    3 - Monopar Therapeutics (0001645469) (Issuer)

    3/4/26 5:25:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Parikh Anand Kiran

    4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)

    2/19/26 9:45:04 PM ET
    $SNSE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADCT
    $AFMD
    $ASTR
    Leadership Updates

    Live Leadership Updates

    View All

    Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer

    WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d

    3/2/26 8:00:00 AM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points

    Issued on behalf of GT Biopharma, Inc. USA News Group News Commentary VANCOUVER, BC, Dec. 4, 2025 /PRNewswire/ -- Triple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die to trigger powerful immune responses[1], while breakthrough natural killer cell research is revealing new pathways to supercharge the body's innate tumor-fighting capabilities[2]. These developments position GT Biopharma, Inc. (NASDAQ:GTBP), Geron Corporation (NASDAQ:GERN), Kura Oncology, Inc. (NASDAQ:KURA), SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), and TScan Therapeutics, Inc. (NASDAQ:TCRX). The FDA's November approval of the f

    12/4/25 12:20:00 PM ET
    $GERN
    $GTBP
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACXP
    $ADCT
    $AFMD
    $ASTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Monopar Therapeutics Inc.

    SC 13D/A - Monopar Therapeutics (0001645469) (Subject)

    12/17/24 5:01:42 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

    SC 13G/A - ADC Therapeutics SA (0001771910) (Subject)

    11/14/24 9:00:57 PM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by The OLB Group Inc.

    SC 13G/A - OLB GROUP, INC. (0001314196) (Subject)

    11/14/24 5:17:38 PM ET
    $OLB
    Real Estate

    $ACXP
    $ADCT
    $AFMD
    $ASTR
    Financials

    Live finance-specific insights

    View All

    Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

    STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the full year and fourth quarter ended December 31, 2025. Highlights of the fourth quarter ended December 31, 2025, or in some cases shortly thereafter, include:In October 2025, the Company received gross proceeds from the exercise of 170,068 Series F Warrants of approximately $1.4 million.Also in October 2025, we were one of five companies to make a formal presentation at IDWeek in Atlanta

    3/13/26 7:01:00 AM ET
    $ACXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update

    LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026Recent amendment to HealthCare Royalty financing agreement increases strategic flexibilityFourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028Company to host conference call today at 8:30 a.m. EDTLAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results f

    3/10/26 7:30:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026

    LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, March 10, 2026, at 8:30 a.m. EDT to report financial results for the fourth quarter and full year ended December 31, 2025, and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you

    3/3/26 7:15:00 AM ET
    $ADCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACXP
    $ADCT
    $AFMD
    $ASTR
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Monopar Therapeutics Inc. on Jun 21 Indicate?

    Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan

    6/22/24 8:00:00 PM ET
    $MNPR
    Biotechnology: Pharmaceutical Preparations
    Health Care